Ann: European Orphan Designation granted for PBT434 for MSA, page-16

It is a good entry price and i bought more at 1.3/1.4 cent mark. Medium term future:


Positives :

1. ann of P2 for pb434 coming very close
2. Possible ann around pbt2 for non neuro diseases
3. pbt434 is successful in P2 and moves to P3

Negatives:

1. dilution for equity raise to fund P2
2. Possible Reverse split ( which almost always ends in further dilution)
3. GK still around
4. Always possible take over
5. pbt434 fails p2

It comes down to which announcement and in what order comes first,

Question is what price will ATHE once it is in the middle of a P2 trial?

If i missed anything important please share.